Drug major Cipla on Thursday slashed the prices by up to 76 per cent of its generic drugs, used in treating cancers of brain, lung and kidney.
The price of Soranib used for treating kidney cancer has been cut by 76 per cent to Rs 1,710 for a month's therapy, from Rs 6,990, Cipla said in a statement.
Brain cancer drug Temoside in 250 mg strength would be available at Rs 5,000 against Rs 20,250 earlier. While lung cancer drug Gefticip 250 Mg in packs of 30 tablets is priced at Rs 4,250 against Rs 10,200.
The move comes on the back of the government permitting domestic firm Natco Pharma to manufacture and sell cancer treatment drug Nexavar at a price over 30 times lower than charged by its patent-holder Bayer Corporation.
In an order by Controller of Patents in March Natco was allowed to sell the drug at a price not exceeding Rs 8,880 for a pack of 120 tablets required for a month's treatment as compared to a whopping Rs 2.80 lakh per month charged by Bayer for its patented Nexavar drug.
Commenting on the development, Cipla Chairman and MD YK Hamied said: "This initiative of price reduction is a humanitarian approach by Cipla to support cancer patients".